Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620885 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL2200251 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL14703475 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL2200099 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL2200706 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL656152 | 0.94 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1TBXA2R | |
| SCHEMBL3250399 | 0.90 | CCR1 (0.55) | CCR1CHRM2CCR5HRH1 | |
| SCHEMBL3249326 | 0.90 | CCR1 (0.55) | CCR1CHRM2CCR5HRH1 | |
| SCHEMBL6859704 | 0.89 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1 | |
| SCHEMBL13620890 | 0.88 | CCR1 (0.47) | CCR1CHRM2CCR5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | claimed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | claimed |
| US-8394817-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | claimed |
| US-20110230516-A1 | CCR1 Antagonists and Methods of Use Therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | claimed |
| US-7977350-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | claimed |
| EP-1669356-B1 | CCR1 Antagonists for the treatment of i.a demyelinating inflammatory disease | MILLENNIUM PHARM INC (US) | 2010-05-19 | — | — | EP | claimed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20130289063-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8394817-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110230516-A1 | CCR1 Antagonists and Methods of Use Therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7977350-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977350-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7732459-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1669356-B1 | CCR1 Antagonists for the treatment of i.a demyelinating inflammatory disease | MILLENNIUM PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1669356-A1 | CCR1 Antagonists for the treatment of i.a demyelinating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1562954-B1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20130289063-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1966/4885CCR5 5/4885 |
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20110230516-A1 | CCR1 Antagonists and Methods of Use Therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | CCR1, CCR3, CCR4 | CCR1 1/4885CHRM2 386/4885CCR5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.